Tumor-Specific Systemic Treatment in Advanced Breast Cancer – How Long does it Make Sense?

Por Wuerstlein, Rachel, Bauerfeind, Ingo
Publicado em 2011

Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer

Por Bauerfeind, Ingo, Elling, Dirk, Heinemann, Volker
Publicado em 2010

News from the San Antonio Breast Cancer Symposium 2009

Por Untch, Michael, Bauerfeind, Ingo, Jackisch, Christian, Kühn, Thorsten, Müller, Volkmar
Publicado em 2010

Node-positive Breast Cancer: Which Are the Best Chemotherapy Regimens?

Por Janni, Wolfgang, Rack, Brigitte, Harbeck, Nadja, Bauerfeind, Ingo, Sommer, Harald, Friese, Klaus
Publicado em 2008

eHealth in Modern Patient-Caregiver Communication: High Rate of Acceptance Among Physicians for Additional Support of Breast Cancer Patients During Long-Term Therapy

Por Kirkovits, Thomas, Schinkoethe, Timo, Drewes, Caroline, Gehring, Caroline, Bauerfeind, Ingo, Harbeck, Nadia, Wuerstlein, Rachel
Publicado no JMIR Cancer (2016)

Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids

Por Halfter, Kathrin, Hoffmann, Oliver, Ditsch, Nina, Ahne, Mareike, Arnold, Frank, Paepke, Stefan, Grab, Dieter, Bauerfeind, Ingo, Mayer, Barbara
Publicado no J Transl Med (2016)

Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study

Por Halfter, Kathrin, Ditsch, Nina, Kolberg, Hans-Christian, Fischer, Holger, Hauzenberger, Tanja, von Koch, Franz Edler, Bauerfeind, Ingo, von Minckwitz, Gunter, Funke, Ilona, Crispin, Alexander, Mayer, Barbara
Publicado no BMC Cancer (2015)

The Reality in the Surveillance of Breast Cancer Survivors—Results of a Patient Survey

Por Stemmler Hans-Joachim, Lässig Dorit, Stieber Petra, Bauerfeind Ingo, Kahlert Steffen, Fasching Peter Alexander, Beckmann Matthias Wilhelm, Glattes Margrit, Goldmann-Posch Ursula, Hoffmann Verena, Untch Michael, Heinemann Volker
Publicado em 2008-01-01